Most Read Articles
Elaine Soliven, 12 Dec 2020
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.

Low DHEA-S levels up risk of heart failure, death

06 Jan 2021

Low levels of dehydroepiandrosterone-sulfate (DHEA-S) contribute to a higher risk of heart failure (HF) and mortality, but not coronary heart disease (CHD), according to a study.

To examine the link between low DHEA-S/DHEA-S change and incident HF hospitalization, CHD, and mortality in older adults, the investigators measured stored plasma from visits 4 (1996–1998) and 5 (2011–2013) of the Atherosclerosis Risk in Communities Study. A total of 8,143 individuals (mean age, 63 years) without prevalent cardiovascular disease were included. Follow-up for incident events was 18 years for DHEA-S level and 5.5 years for change in DHEA-S.

DHEA-S below the 15th sex-specific percentile of the study population (men: 55.4 µg/dL; women: 27.4 µg/dL) correlated with a higher risk of HF hospitalization (men: hazard ratio [HR], 1.30, 95 percent confidence interval [CI], 1.07–1.58; women: HR, 1.42, 95 percent CI, 1.13–1.79).

Moreover, DHEA-S below the 25th sex-specific percentile (men: 70.0 µg/dL; women: 37.1 µg/dL) correlated with a higher risk of mortality (men: HR, 1.12, 95 percent CI, 1.01–1.25; women: HR, 1.19, 95 percent CI, 1.03–1.37).

Greater percentage decrease in DHEA-S in men was associated with an increased risk of HF hospitalization (HR, 1.94, 95 percent CI, 1.11–3.39), but not in women. Of note, low DHEA-S and change in DHEA-S did not correlate with incident CHD.

“Further investigation is warranted to evaluate mechanisms underlying these associations,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 12 Dec 2020
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.